Truist Financial’s Columbia Research Enhanced Value ETF REVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-133,957
Closed -$2.73M 2703
2023
Q3
$2.73M Sell
133,957
-5,097
-4% -$107K ﹤0.01% 1082
2023
Q2
$2.91M Sell
139,054
-2,386
-2% -$48K ﹤0.01% 1079
2023
Q1
$2.81M Sell
141,440
-4,012
-3% -$80.5K ﹤0.01% 1073
2022
Q4
$2.84M Buy
145,452
+6,554
+5% +$129K 0.01% 1041
2022
Q3
$2.49M Sell
138,898
-827
-0.6% -$16.2K ﹤0.01% 1062
2022
Q2
$2.65M Buy
+139,725
New +$2.85M ﹤0.01% 1082
2022
Q1
Sell
-37,082
Closed -$792K 2821
2021
Q4
$792K Buy
37,082
+16,800
+83% +$352K ﹤0.01% 1766
2021
Q3
$408K Buy
20,282
+6,138
+43% +$126K ﹤0.01% 2125
2021
Q2
$0 Buy
+14,144
New +$283K ﹤0.01% 2796

Other funds holding REVS

Truist Financial's REVS Position: Q4 2023 in Review

Truist Financial sold out of Columbia Research Enhanced Value ETF (REVS) in Q4 2023, closing a stake of 133,957 shares — an estimated $2.73M sold.

Truist Financial first reported a position in REVS in Q2 2021 and held it in 9 quarters. The position peaked at $2.91M in Q2 2023. 13 funds tracked by Wall St. Rank hold REVS as of Q4 2023.

  • Truist Financial reported no remaining Columbia Research Enhanced Value ETF position as of Q4 2023 after selling out during the quarter.
  • Truist Financial sold 133,957 Columbia Research Enhanced Value ETF shares in Q4 2023, an estimated $2.73M.
  • Truist Financial first reported a position in Columbia Research Enhanced Value ETF in Q2 2021 and held it in 9 quarters.
  • Truist Financial's Columbia Research Enhanced Value ETF position peaked at $2.91M in Q2 2023.
  • 13 funds tracked by Wall St. Rank held Columbia Research Enhanced Value ETF as of Q4 2023.

Based on Truist Financial's 13F filing for Q4 2023, filed 2 Feb 2024.